Related Experiment Video
Updated: Jun 6, 2025
A Stably Established Two-Point Injection of Lysophosphatidylcholine-Induced Focal Demyelination Model in Mice
Published on: May 11, 2022
Propionic Acid Impact on Multiple Sclerosis: Evidence and Challenges
Lorena Lorefice1, Magdalena Zoledziewska2
1Multiple Sclerosis Center, ASL Cagliari, Department of Medical Sciences and Public Health, Binaghi Hospital, University of Cagliari, via Is Guadazzonis 2, 09126 Cagliari, Italy.
Abstract:
Accumulating evidence suggests that multiple sclerosis (MS) is an environmentally influenced disorder with contributions from life-time exposure to factors including Epstein-Barr virus infection or shifts in microbiome, diet and lifestyle. One suggested factor is a deficiency in propionic acid, a short-chain fatty acid produced by gut bacteria that may contribute to the disease pathology both in animal models and in human cases of MS. Propionate appears to exert beneficial effects on the immune, peripheral and central nervous systems of people with MS (pwMS), showing immunoregulatory, neuroprotective and neurogenerative effects. These functions are crucial, given that MS is characterized by immune-mediated damage of myelin in the central nervous system. Accordingly, propionate supplementation or a modulated increase in its levels through the microbiome and diet may help counteract the pro-inflammatory state in MS by directly regulating immune system and/or by decreasing permeability of gut barrier and blood-brain barrier. This could potentially improve outcomes when used with immune-modulating therapy. However, while its broad effects are promising, further large clinical trials are necessary to evaluate its efficacy and safety in pwMS and clarify its role as a complementary therapeutic strategy. This review provides a comprehensive analysis of the evidence, challenges and limitations concerning propionic acid supplementation in MS.
Insights
Propionic acid, a gut bacteria byproduct, may help manage multiple sclerosis (MS) by regulating the immune system and protecting the nervous system. Further clinical trials are needed to confirm its efficacy and safety for people with MS.
Area of Science:
- Neuroimmunology
- Microbiome research
- Metabolic disorders
Background:
- Multiple sclerosis (MS) is an immune-mediated central nervous system disorder influenced by environmental factors.
- Gut microbiome alterations and deficiencies in short-chain fatty acids like propionic acid are implicated in MS pathology.
- Propionic acid exhibits potential immunoregulatory and neuroprotective effects relevant to MS.
Purpose of the Study:
- To comprehensively review the evidence for propionic acid's role in multiple sclerosis.
- To analyze the potential benefits of propionic acid supplementation in managing MS.
- To discuss the challenges and limitations of using propionic acid as a complementary therapy for MS.
Main Methods:
- Literature review of studies on propionic acid, gut microbiome, and multiple sclerosis.
- Analysis of preclinical and clinical data regarding propionic acid's effects on immune and nervous systems.
- Evaluation of proposed mechanisms of action, including immune modulation and barrier integrity.
Main Results:
- Propionic acid demonstrates immunomodulatory, neuroprotective, and neurogenerative properties.
- Increased propionic acid levels may counteract inflammation and improve barrier function in MS.
- Potential benefits include direct immune system regulation and reduced gut and blood-brain barrier permeability.
Conclusions:
- Propionic acid supplementation shows promise as a complementary strategy for multiple sclerosis.
- Further large-scale clinical trials are essential to establish efficacy and safety in people with MS.
- Clarifying propionic acid's role could lead to novel therapeutic approaches for MS management.
